Lithium neurotoxicity at subtherapeutic serum levels.
Prettyman
R
R
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001259:Ataxia / Q000097:blood / Q000139:chemically induced*; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D016651:Lithium Carbonate / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D008297:Male; D009207:Myoclonus / Q000097:blood / Q000139:chemically induced*; D019965:Neurocognitive Disorders / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D009460:Neurologic Examination / Q000187:drug effects
D014150:Antipsychotic Agents; D016651:Lithium Carbonate; D002220:Carbamazepine